<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2393-6797</journal-id>
<journal-title><![CDATA[Revista Uruguaya de Medicina Interna ]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Urug. Med. Int.]]></abbrev-journal-title>
<issn>2393-6797</issn>
<publisher>
<publisher-name><![CDATA[Sociedad de Medicina Interna del Uruguay]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2393-67972023000100004</article-id>
<article-id pub-id-type="doi">10.26445/08.01.1</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Anticuerpos Anti Ro 52/Ro 60 y su correlación clínica- serológica. Estudio descriptivo unicéntrico.]]></article-title>
<article-title xml:lang="en"><![CDATA[Anti Ro 52/Ro 60 antibodies and their clinical-serological correlation. Single center descriptive study.]]></article-title>
<article-title xml:lang="pt"><![CDATA[Anticorpos anti Ro 52/Ro 60 e sua correlação clínico-sorológica. Estudo descritivo de centro único.]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rostán]]></surname>
<given-names><![CDATA[Sofía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Consani]]></surname>
<given-names><![CDATA[Sandra]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[Carolina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fernández]]></surname>
<given-names><![CDATA[Lucía]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Yamelli]]></surname>
<given-names><![CDATA[Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de la República Facultad de Medicina Clínica Médica 3]]></institution>
<addr-line><![CDATA[Montevideo ]]></addr-line>
<country>Uruguay</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2023</year>
</pub-date>
<volume>8</volume>
<numero>1</numero>
<fpage>4</fpage>
<lpage>12</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_arttext&amp;pid=S2393-67972023000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_abstract&amp;pid=S2393-67972023000100004&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.edu.uy/scielo.php?script=sci_pdf&amp;pid=S2393-67972023000100004&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Introducción:  La interpretación de los diversos anticuerpos vinculados a las Enfermedades Autoinmunes Sistémicas (EAS) es un reto clínico. Entre los anticuerpos específicos, los anti Ro son los de mayor frecuencia. Se asocian a un fenotipo clínico, relacionados tanto a manifestaciones clínicas diversas como a EAS establecidas.  Metodología : Estudio descriptivo, observacional, transversal, realizado en Hospital Maciel (Montevideo, Uruguay).  Resultados:  Se enrolaron 70 pacientes, la mayoría de sexo femenino. 60 pacientes (85%) presentaron Ro52, 40 (57%) Ro60 y 31 (44%) ambos anticuerpos. Del total de los pacientes que tuvieron Ro positivo en 59 (93%) se evidenciaron manifestaciones clínicas. Las más frecuentes fueron: fotosensibilidad 26 (42%); Raynaud 18 (30%); xerostomía 26 (42%), xeroftalmia 25 (41%), enfermedad pulmonar intersticial 10 (15%), nefropatía 20 (32%), y manifestaciones hematológicas 16 (23%). En 59 casos (86%) se diagnosticó una enfermedad autoinmune. Las más frecuentes fueron Síndrome de Sjögren 26 (41%), Lupus eritematoso sistémico 26 (41%), Artritis reumatoidea 14 (22%), Esclerosis sistémica 10 (16%), Hepatopatías autoinmunes 10 (14%). Se evidenciaron otros autoanticuerpos positivos en el 68 (97%) de los casos. El ANA fue positivo en 67 pacientes (95%). La proporción de pacientes con Ro60 positivo fue significativamente mayor en pacientes que presentaron fotosensibilidad (p 0.006), Lupus cutáneo agudo (p 0.003), manifestaciones articulares (p 0.031) y nefropatía (p 0.016). La positividad de ambos Ro52/60 fue significativamente mayor en pacientes con manifestaciones musculares (p 0.028) y nefropatía (p 0.047). En cuanto al tipo de enfermedad autoinmune se evidenció una proporción significativa de pacientes con Ro60 y LES (p 0.004), así como de ambos anticuerpos y ES (p 0.04). Hubo mayor proporción de pacientes con Ro60 y anti SCL 70 (p 0.008) que aquellos que no lo presentaban, así mismo sucede con Ro60 y el FR (p 0.018); y Ro 52/60 con anti La (p 0.049) y anti SCL 70 (p 0.027).  Conclusiones:  Los anticuerpos específicos Ro52/60 son frecuentes, predominando el Ro52. La mayoría de los pacientes que presentan positividad tienen una enfermedad autoinmune de base, observándose también en pacientes con patología oncológica. Conocer sus asociaciones es de suma importancia dado que presentan un rol diagnóstico, pronostico, y ayudan a predecir el fenotipo clínico.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Introduction:  The interpretation of the various antibodies linked to systemic autoimmune diseases is a clinical challenge. Among the specific antibodies, anti Ro are the most frequent. They are associated with a clinical phenotype, related to both diverse clinical manifestations and established SAD.  Methodology:  descriptive, observational, cross-sectional study carried out at the Maciel Hospital, Montevideo, Uruguay.  Results:  70 patients were enrolled, most of them female. 60 patients (85%) presented Ro52, 40 (57%) Ro60 and 31 (44%) both antibodies. Of the total number of patients who had positive Ro in 59 (93%) clinical manifestations were evidenced. The most frequent were: photosensitivity 26 (42%); Raynaud 18 (30%); Xerostomia 26 (42%), Xerophthalmia 25 (41%), interstitial lung disease 10 (15%), nephropathy 20 (32%), and hematological manifestations 16 (23%). In 59 cases (86%) an autoimmune disease was diagnosed. The most frequent were: Sjögrens syndrome 26 (41%), systemic lupus erythematosus 26 (41%), rheumatoid arthritis 14 (22%), systemic sclerosis 10 (16%), autoimmune liver diseases 10 (14%). Other positive autoantibodies were found in 68 (97%) of the cases. ANA was positive in 67 patients (95%). The proportion of patients with positive Ro60 was significantly higher in patients with photosensitivity (p: 0.006), acute cutaneous lupus (p: 0.003), joint manifestations (p: 0.031), and nephropathy (p: 0.016). The positivity of both Ro52/60 was significantly higher in patients with muscular manifestations (p 0.028) and nephropathy (p 0.047). Regarding the type of autoimmune disease, there was a significant proportion of patients with Ro60 and SLE (p 0.004), as well as both antibodies and SE (p 0.04). There was a higher proportion of patients with Ro60 and anti SCL 70 (p 0.008) than those who did not, the same happens with Ro60 and RF (p 0.018); and Ro 52/60 with anti La (p 0.049) and anti SCL 70 (p 0.027).  Conclusions:  Ro52/60 specific antibodies are frequent, predominating Ro52. Most of the patients who present positivity have an underlying autoimmune disease, which is also observed in patients with oncological pathology. Knowing their associations is of the utmost importance given that they present a diagnostic and prognostic role, and help to predict the clinical phenotype.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo:  Introdução:  A interpretação dos vários anticorpos ligados a doenças autoimunes sistêmicas é um desafio clínico. Dentre os anticorpos específicos, os anti Ro são os mais frequentes. Eles estão associados a um fenótipo clínico, relacionado tanto a várias manifestações clínicas quanto a EAS estabelecido.  Metodologia:  estudo descritivo, observacional, transversal, realizado no Hospital Maciel, Montevidéu, Uruguai.  Resultados:  foram incluídos 70 pacientes, a maioria do sexo feminino. 60 pacientes (85%) apresentaram Ro52, 40 (57%) Ro60 e 31 (44%) ambos os anticorpos. Do total de pacientes que apresentaram Ro positivo em 59 (93%) manifestações clínicas foram evidenciadas. Os mais frequentes foram: fotossensibilidade 26 (42%); Raynaud 18 (30%); Xerostomia 26 (42%), Xeroftalmia 25 (41%), doença pulmonar intersticial 10 (15%), nefropatia 20 (32%) e manifestações hematológicas 16 (23%). Em 59 casos (86%) foi diagnosticada doença autoimune. As mais frequentes foram: síndrome de Sjögren 26 (41%), lúpus eritematoso sistêmico 26 (41%), artrite reumatoide 14 (22%), esclerose sistêmica 10 (16%), hepatopatias autoimunes 10 (14%). Outros autoanticorpos positivos foram encontrados em 68 (97%) dos casos. O ANA foi positivo em 67 pacientes (95%). A proporção de pacientes com Ro60 positiva foi significativamente maior em pacientes com fotossensibilidade (p: 0,006), lúpus cutâneo agudo (p: 0,003), manifestações articulares (p: 0,031) e nefropatia (p: 0,016). A positividade de ambos Ro52/60 foi significativamente maior em pacientes com manifestações musculares (p 0,028) e nefropatia (p 0,047). Em relação ao tipo de doença autoimune, houve proporção significativa de pacientes com Ro60 e LES (p 0,004), assim como anticorpos e SE (p 0,04). Houve maior proporção de pacientes com Ro60 e anti SCL 70 (p 0,008) do que aqueles que não apresentaram, o mesmo ocorre com Ro60 e RF (p 0,018); e Ro 52/60 com anti La (p 0,049) e anti SCL 70 (p 0,027).  Conclusões:  Anticorpos específicos Ro52/60 são frequentes, predominando Ro52. A maioria dos pacientes que apresentam positividade tem uma doença autoimune de base, também observada em pacientes com patologia oncológica. Conhecer suas associações é de extrema importância, pois têm papel diagnóstico e prognóstico, além de ajudar a predizer o fenótipo clínico.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[anticuerpos Ro52/60]]></kwd>
<kwd lng="es"><![CDATA[autoinmunidad]]></kwd>
<kwd lng="en"><![CDATA[Ro52/60 antibodies]]></kwd>
<kwd lng="en"><![CDATA[autoimmunity]]></kwd>
<kwd lng="pt"><![CDATA[Anticorpos Ro52/60]]></kwd>
<kwd lng="pt"><![CDATA[autoimunidade]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Oliva Menacho]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Arroyo Acevedo]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Oliva Candela]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Salas Ponce]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Garcia Hjarles]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Relación entre los anticuerpos contra antígenos extraíbles del núcleo y las enfermedades del tejido conectivo identificados por Immunoblots en un hospital y universidad de Lima]]></article-title>
<source><![CDATA[Rev. argent. reumatolg]]></source>
<year>2020</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>25-30</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sherer]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Gorstein]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fritzler]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shoenfeld]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Autoantibody explosion in systemic lupus erythematosus more than 100 different antibodies found in SLE patients]]></article-title>
<source><![CDATA[Semin Arthritis Rheum]]></source>
<year>2004</year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>501-37</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sawalha]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Harley]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antinuclear autoantibodies in systemic lupus erythematosus]]></article-title>
<source><![CDATA[Curr Opin Rheumatol]]></source>
<year>2004</year>
<volume>16</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>534-40</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Franceschini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Cavazzana]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Ro/SSA and La/SSB antibodies]]></article-title>
<source><![CDATA[Autoimmunity]]></source>
<year>2005</year>
<volume>38</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>55-63</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghillani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Toly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rouquette]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Bengoufa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nicaise]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies results of a multicentric study]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2011</year>
<volume>10</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>509-13</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
<name>
<surname><![CDATA[Pan]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Kurien]]></surname>
<given-names><![CDATA[BT]]></given-names>
</name>
<name>
<surname><![CDATA[James]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Harley]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Scofield]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Immunization with vesicular stomatitis virus nucleocapsid protein induces autoantibodies to the 60 kD Ro ribonucleoprotein particle]]></article-title>
<source><![CDATA[J Investig Med]]></source>
<year>1995</year>
<volume>43</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151-8</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vitali]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Bombardieri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Jonsson]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Moutsopoulos]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Alexander]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Carsons]]></surname>
<given-names><![CDATA[SE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Classification criteria for Sjogren's syndrome a revised version of the European criteria proposed by the American-European Consensus Group]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2002</year>
<volume>61</volume>
<page-range>554-8</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mendez-Rayo]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ochoa-Zárate]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Posso-Osorio]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Naranjo-Escobar]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Tobón]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Interpretación de los anticuerpos en enfermedades reumatológicas]]></article-title>
<source><![CDATA[Rev Colomb reumatol]]></source>
<year>2018</year>
<volume>25</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>112-25</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sontheimer]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Skin manifestations of systemic autoimmune connective tissue disease diagnostics and therapeutics]]></article-title>
<source><![CDATA[Best Pract Res Clin Rheumatol]]></source>
<year>2004</year>
<volume>18</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>429-62</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodsaward]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Chottawornsak]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Suwanchote]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rachayon]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Deekajorndech]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wright]]></surname>
<given-names><![CDATA[HL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The clinical significance of antinuclear antibodies and specific autoantibodies in juvenile and adult systemic lupus erythematosus patients]]></article-title>
<source><![CDATA[Asian Pac J Allergy Immunol]]></source>
<year>2021</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ponce]]></surname>
<given-names><![CDATA[YM]]></given-names>
</name>
<name>
<surname><![CDATA[Zalazar]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[García Coello]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Rillo]]></surname>
<given-names><![CDATA[OL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Serie de casos clínicos de pacientes con Miopatía inflamatoria idiopática y Enfermedad pulmonar intersticial del registro de Miopatías inflamatorias idiopáticas de la Sociedad Argentina de Reumatología]]></article-title>
<source><![CDATA[Rev. argent. reumatolg]]></source>
<year>2020</year>
<volume>31</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>12-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shi]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Peng]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>2017</year>
<volume>44</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1051-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[La Corte]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Lo Monaco]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Locaputo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Dolzani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Trotta]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease]]></article-title>
<source><![CDATA[Autoimmunity]]></source>
<year>2006</year>
<volume>39</volume>
<page-range>249-53</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghillani]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[André]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Toly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rouquette]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Bengoufa]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nicaise]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60 kDa antibodies: Results of a multicentric study]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2011</year>
<volume>10</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>509-13</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menor Almagro]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez Arjona]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Marín Dueñas]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Páez-Camino Carrillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[De la Iglesia Salgado]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Utilidad clínica de los anticuerpos antI-SSA y/o anti-SSB en el hospital de Jeréz. Estudio de los últimos 10 años.]]></article-title>
<source><![CDATA[Rev Clin Esp]]></source>
<year>2013</year>
<volume>213</volume>
<page-range>935</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Granito]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Muratori]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Muratori]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pappas]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Cassani]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Worthington]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis]]></article-title>
<source><![CDATA[Aliment Pharmacol Ther]]></source>
<year>2007</year>
<volume>26</volume>
<page-range>831-8</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Montano-Loza]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Shums]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Norman]]></surname>
<given-names><![CDATA[GL]]></given-names>
</name>
<name>
<surname><![CDATA[Czaja]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic implications of antibodies to Ro/SSA and soluble liver antigen in type 1 autoimmune hepatitis]]></article-title>
<source><![CDATA[Liver Int]]></source>
<year>2012</year>
<volume>32</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>85-92</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ovalles-Bonilla]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Nieto]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez-Barrio]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez-Longo]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Janta]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[SAT0509 Clinical and Serological Profile of Children with Positive SSARo/SSB-La Antibodies]]></article-title>
<collab>Naredo E et al</collab>
<source><![CDATA[Ann rheum dis]]></source>
<year>2015</year>
<volume>74</volume>
<page-range>844-5</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[LeFeber]]></surname>
<given-names><![CDATA[WP]]></given-names>
</name>
<name>
<surname><![CDATA[Norris]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Ryan]]></surname>
<given-names><![CDATA[SR]]></given-names>
</name>
<name>
<surname><![CDATA[Huff]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Kubo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>1984</year>
<volume>74</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1545-51</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diez Morrondo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Lema Gontad]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez Rivas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Atanes Sandoval]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos actuales del síndrome de Sjogren etiopatogenia, manifestaciones clínicas, diagnóstico y tratamiento]]></article-title>
<collab>De Toro Santos FJ.Pinto Tasende JA</collab>
<source><![CDATA[Semin Fund Esp Reumatol]]></source>
<year>2010</year>
<volume>11</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>70-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gerli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Muscat]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Giansanti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Danieli]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Sciuto]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gabrielli]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Quantitative assessment of salivary gland inflammatory infiltration in primary Sjogren&amp;apos;s syndrome its relationship to different demographic, clinical and serological features of the disorder]]></article-title>
<source><![CDATA[Br J Rheumatol]]></source>
<year>1997</year>
<volume>36</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>969-75</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robles]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos-Casals]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Significado clínico de los anticuerpos antinucleares]]></article-title>
<source><![CDATA[Serv Enfermedades Sist Barcelona]]></source>
<year>2005</year>
<page-range>85-90</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Consani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Torres]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Alonso]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Berez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estudio multicéntrico descriptivo de enfermedades pulmonares intersticiales asociadas a enfermedades autoinmunes en centros de salud de Montevideo, Uruguay Rev. Urug. Med]]></article-title>
<source><![CDATA[Int]]></source>
<year>2018</year>
<volume>3</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>12-9</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buvry]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cassagnes]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tekath]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Artigues]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pereira]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Rieu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-Ro52 antibodies are a risk factor for interstitial lung disease in primary Sjögren syndrome]]></article-title>
<source><![CDATA[Respir Med]]></source>
<year>2020</year>
<volume>163</volume>
<page-range>105895</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
